Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Acute Myeloid Leukemia (AML) Panel By PCR is typically 5-7 business days from the date of sample collection.

What are the prerequisites for the test Acute Myeloid Leukemia (AML) Panel By PCR

  • Specimen Type: Bone marrow
  • Specimen Container: Lavender top (EDTA) tube
  • Specimen Volume: 2 mL
  • Collection Instructions: Collect bone marrow in a lavender top tube and store at room temperature
  • Transport Temperature: Room temperature
  • Stability: Stable at room temperature for 72 hours
  • Rejection Criteria: Clotted specimens, frozen specimens, specimens collected in heparin or sodium citrate tubes

What are the measure values for the test Acute Myeloid Leukemia (AML) Panel By PCR

  • FLT3-ITD: Positive or Negative
  • NPM1: Positive or Negative
  • CEBPA: Positive or Negative
  • DNMT3A: Positive or Negative
  • IDH1: Positive or Negative
  • IDH2: Positive or Negative

What does this test Acute Myeloid Leukemia (AML) Panel By PCR identify?

  • FLT3-ITD mutation: This test detects internal tandem duplication mutations in the FLT3 gene, which are commonly found in AML and associated with poor prognosis.
  • NPM1 mutation: This test identifies mutations in the NPM1 gene, which are also frequently found in AML and are associated with a favorable prognosis.
  • CEBPA mutation: This test detects mutations in the CEBPA gene, which are associated with a better response to treatment in AML patients.
  • IDH1/IDH2 mutation: This test identifies mutations in the IDH1 and IDH2 genes, which are found in a subset of AML patients and may impact treatment decisions.

Why is this test Acute Myeloid Leukemia (AML) Panel By PCR taken?

Acute Myeloid Leukemia (AML) Panel By PCR Test

The Acute Myeloid Leukemia (AML) Panel By PCR test is taken to diagnose and monitor Acute Myeloid Leukemia, a type of blood cancer that affects the bone marrow and blood cells. This test is used to detect specific genetic mutations or abnormalities in the DNA of leukemia cells that can help in confirming the diagnosis, determining the prognosis, and guiding treatment decisions.

PCR (Polymerase Chain Reaction) is a sensitive molecular technique that amplifies and detects specific DNA sequences, allowing for the identification of genetic mutations associated with AML. The results of this test can provide valuable information to healthcare providers about the presence of AML, the subtype of AML, and the response to treatment.

Overall, the Acute Myeloid Leukemia (AML) Panel By PCR test is an important tool in the diagnosis and management of AML, helping healthcare providers to tailor treatment plans and improve outcomes for patients with this type of leukemia.

No FAQs available.

Customer Google Rating